International Stem Cell (ISCO) Preferred Stock Liabilities (2012 - 2026)
International Stem Cell (ISCO) posted quarterly Preferred Stock Liabilities of $4.3 million for Q4 2025, little changed year-over-year from $4.3 million in Q4 2024, and little changed quarter-over-quarter from $4.3 million in Q3 2025.
International Stem Cell (ISCO) Preferred Stock Liabilities (2012 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Preferred Stock Liabilities for 10 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $4.3 million (changed 0.0% YoY), while the FY2025 annual figure was $4.3 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities steadied at $4.3 million in Q4 2025 per ISCO's latest filing, from $4.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $4.3 million in Q1 2021 and bottomed at $4.3 million in Q1 2021.
- Historically, Preferred Stock Liabilities has averaged $4.3 million across 5 years, with a median of $4.3 million in 2021.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 0.0% in 2021 and fell as far as 0.0% in 2021.
- International Stem Cell's Preferred Stock Liabilities stood at $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022, then changed by 0.0% to $4.3 million in 2023, then changed by 0.0% to $4.3 million in 2024, then changed by 0.0% to $4.3 million in 2025.
- Business Quant data shows ISCO's Preferred Stock Liabilities at $4.3 million in Q4 2025, $4.3 million in Q3 2025, and $4.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | 4.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.30 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 4.30 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.30 Mn |
| Jun 30, 2023 | 4.30 Mn |
| Mar 31, 2023 | 4.30 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.30 Mn |
| Jun 30, 2022 | 4.30 Mn |
| Mar 31, 2022 | 4.30 Mn |
| Dec 31, 2021 | 4.30 Mn |
| Sep 30, 2021 | 4.30 Mn |
| Jun 30, 2021 | 4.30 Mn |